(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 14.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 291.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.8%.
Vanda Pharmaceuticals's revenue in 2025 is $212,074,000.On average, 6 Wall Street analysts forecast VNDA's revenue for 2025 to be $13,157,273,703, with the lowest VNDA revenue forecast at $12,497,755,312, and the highest VNDA revenue forecast at $13,738,193,576. On average, 6 Wall Street analysts forecast VNDA's revenue for 2026 to be $15,995,093,876, with the lowest VNDA revenue forecast at $13,690,916,272, and the highest VNDA revenue forecast at $17,994,923,835.
In 2027, VNDA is forecast to generate $19,886,015,995 in revenue, with the lowest revenue forecast at $16,274,029,969 and the highest revenue forecast at $22,295,385,600.